1. Home
  2. XBIT vs RNXT Comparison

XBIT vs RNXT Comparison

Compare XBIT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$1.88

Market Cap

69.8M

Sector

Health Care

ML Signal

N/A

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

N/A

Current Price

$1.14

Market Cap

79.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XBIT
RNXT
Founded
2005
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
79.4M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
XBIT
RNXT
Price
$1.88
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.13
AVG Volume (30 Days)
92.8K
★ 360.8K
Earning Date
11-20-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 20.00
EPS
N/A
★ N/A
Revenue
N/A
★ $1,123,000.00
Revenue This Year
N/A
$244.84
Revenue Next Year
$30.47
$195.26
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 2511.63
52 Week Low
$1.80
$0.70
52 Week High
$3.44
$2.59

Technical Indicators

Market Signals
Indicator
XBIT
RNXT
Relative Strength Index (RSI) 39.12 36.64
Support Level $1.80 $1.09
Resistance Level $2.42 $1.30
Average True Range (ATR) 0.12 0.12
MACD -0.00 -0.00
Stochastic Oscillator 27.27 36.72

Price Performance

Historical Comparison
XBIT
RNXT

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: